Towards the sustainable discovery and development of new antibiotics.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Arimondo, Paola B
Bode, Helge B
Medema, Marnix H
Tormo, José Rubén
Truman, Andrew W
Weissman, Kira J
Hirsch, Anna K H
van Dongen, Maarten
Piddock, Laura J V
Gilbert, Ian H
Moser, Heinz E
MetadataShow full item record
AbstractAn ever-increasing demand for novel antimicrobials to treat life-threatening infections caused by the global spread of multidrug-resistant bacterial pathogens stands in stark contrast to the current level of investment in their development, particularly in the fields of natural-product-derived and synthetic small molecules. New agents displaying innovative chemistry and modes of action are desperately needed worldwide to tackle the public health menace posed by antimicrobial resistance. Here, our consortium presents a strategic blueprint to substantially improve our ability to discover and develop new antibiotics. We propose both short-term and long-term solutions to overcome the most urgent limitations in the various sectors of research and funding, aiming to bridge the gap between academic, industrial and political stakeholders, and to unite interdisciplinary expertise in order to efficiently fuel the translational pipeline for the benefit of future generations.
CitationNat Rev Chem. 2021 Aug 19:1-24. doi: 10.1038/s41570-021-00313-1. Epub ahead of print. PMID: 34426795.
AffiliationHIPS, Helmholtz-Institut für Pharmazeutische Forschung Saarland, Universitätscampus E8.1 66123 Saarbrücken, Germany.
JournalNature reviews. Chemistry
The following license files are associated with this item:
- Creative Commons
- [Development of antituberculous drugs: current status and future prospects].
- Authors: Tomioka H, Namba K
- Issue date: 2006 Dec
- Multidrug-resistant gram-negative organisms: a review of recently approved antibiotics and novel pipeline agents.
- Authors: Provenzani A, Hospodar AR, Meyer AL, Leonardi Vinci D, Hwang EY, Butrus CM, Polidori P
- Issue date: 2020 Aug
- Recent Progress in the Development of Small-Molecule FtsZ Inhibitors as Chemical Tools for the Development of Novel Antibiotics.
- Authors: Carro L
- Issue date: 2019 Nov 11
- 10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America.
- Authors: Boucher HW, Talbot GH, Benjamin DK Jr, Bradley J, Guidos RJ, Jones RN, Murray BE, Bonomo RA, Gilbert D, Infectious Diseases Society of America.
- Issue date: 2013 Jun
- Innovation in Antimicrobial Resistance: The CARB-X Perspective.
- Authors: Alm RA, Gallant K
- Issue date: 2020 Jun 12